RIGL Q1 2024 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$541M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$30M+13.3% YoY

Gross Profit

$28M93.1% margin

Operating Income

-$7M-23.6% margin

Net Income

-$8M-27.9% margin

EPS (Diluted)

$-0.47

QoQ Revenue Growth

-17.5%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$127M

Total Liabilities

$158M

Stockholders' Equity

-$32M

Cash & Equivalents

$26M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$30M	$26M	+13.3%
Gross Profit	$28M	$25M	+9.6%
Operating Income	-$7M	-$13M	+45.3%
Net Income	-$8M	-$14M	+39.1%

Revenue Segments

Gross product sales

$38M69%

Product sales, net

$26M47%

Revenues from collaborations

$4M6%

Discounts and allowances

-$12M-22%